Medicine and Dentistry
Acute Myeloid Leukemia
100%
Patient
71%
Transplantation
60%
Hematopoietic Stem Cell Transplantation
52%
Allogeneic Hematopoietic Stem Cell Transplantation
41%
Overall Survival
38%
Myelodysplastic Syndrome
38%
Adult
32%
Multiple Myeloma
31%
Stem Cell Therapy
28%
Minimal Residual Disease
27%
Inpatient
25%
Autologous Stem Cell Transplantation
22%
Donor
21%
Therapeutic Procedure
20%
Aplastic Anemia
20%
High Risk Population
18%
Graft Versus Host Reaction
18%
Conditioning
17%
Acute Myelogenous Leukemia
16%
Disease Free Survival
15%
Fludarabine
14%
Survival
13%
Spontaneous Remission
13%
Sibling
13%
Progression Free Survival
12%
Chromosome Aberration
12%
Allogeneic Stem Cell Transplantation
12%
Acute Graft Versus Host Disease
11%
Cytomegalovirus
11%
Engraftment
11%
Graft Versus Host Reaction
11%
Thymocyte Antibody
11%
Peripheral Blood Stem Cell
11%
Low Drug Dose
11%
T Cell
10%
Hazard Ratio
9%
Survival Rate
9%
Graft Failure
9%
Prognostic Factor
9%
Combination Therapy
8%
Chronic Graft Versus Host Disease
8%
Diagnosis
8%
Risk Stratification
8%
Cumulative Incidence
8%
Karyotype
7%
Gene Mutation
7%
Autologous Hematopoietic Stem Cell Transplantation
7%
Acute Promyelocytic Leukemia
7%
Age
7%
Immunology and Microbiology
Myeloid
60%
Hematopoietic Stem Cell Transplantation
34%
Conditioning
32%
Overall Survival
30%
Allogeneic Hematopoietic Stem Cell Transplantation
27%
Graft-Versus-Host Disease
26%
Allogeneic Stem Cell Transplantation
24%
Multiple Myeloma
24%
Aplastic Anemia
22%
Autologous Stem Cell Transplantation
21%
Stem Cell Transplantation
21%
Disease Free Survival
21%
Anti-Thymocyte Globulin
20%
Chronic Graft Versus Host Disease
14%
Peripheral Blood Stem Cell
13%
High Risk Population
12%
Peripheral Blood Stem Cell Transplantation
12%
Transplantation
11%
Acute Graft Versus Host Disease
11%
Engraftment
10%
Tumor Suppressor Gene
10%
Hematopoietic Stem Cell Transplantation
9%
Low Drug Dose
9%
Karyotype
8%
Progression Free Survival
7%
Survival Rate
7%
T Cell
7%
Transplant Procedure
7%
Myeloid
7%
Immunosuppressive Drug
6%
Drug Megadose
5%
Neutrophil
5%
Overall Survival
5%
Recurrence Free Survival
5%
Immunocompetent Cell
5%
Human Leukocyte Antigen
5%
Disease Free Survival
5%
Cell Transplantation
5%
Hematopoietic Cell
5%
Biochemistry, Genetics and Molecular Biology
Overall Survival
24%
Myeloid
15%
Conditioning
15%
Stem Cell Transplantation
14%
Autologous Stem Cell Transplantation
14%
Cytogenetics
14%
Karyotype
13%
Disease Free Survival
12%
Hematopoietic Stem Cell Transplantation
10%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Allogeneic Stem Cell Transplantation
10%
Stem Cell
9%
Host
9%
Chromosomal Aberration
7%
High Risk Population
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Anti-Thymocyte Globulin
6%
Progression Free Survival
6%
Hematopoietic Stem Cell Transplantation
5%
WT1
5%
Cell Transplantation
5%
Fludarabine
5%